Skip to main content

Table 2 The feasible combination therapy to enhance PARPi sensitivity and overcome PARPi resistance

From: PARP inhibitor resistance: the underlying mechanisms and clinical implications

Combination therapyTrialsNCTPhaseTreatmentStatusStudy population
PARPi-oHSVs combinationNo     
PARPi-IR combinationYesNCT00649207IVeliparib + WBRTaCompletedSolid tumors with brain metastases
PARPi-IR combinationYesNCT01264432IVeliparib + IRCompletedPeritoneal carcinomatosis; fallopian tube, ovarian and primary peritoneal cancers
PARPi-IR combinationYesNCT01589419IVeliparib + capecitabine + IRCompletedLocally advanced rectal cancer
PARPi-IR combinationYesNCT02412371I/IIVeliparib + Paclitaxel/Carboplatin + IRCompletedStage III NSCLCb
PARPi-IR combinationYesNCT01386385I/IIVeliparib + Paclitaxel/Carboplatin + IRActive, not recruitingStage III NSCLC
PARPi-IR combinationYesNCT01618357IVeliparib + IRRecruitingBreast cancer
PARPi-CDKi combinationNo     
PARPi-immunotherapyYesNCT02734004I/IIOlaparib + MED14736Active, not recruitingOvarian, breast, SCLC cand gastric cancers
PARPi-immunotherapyYesNCT03824704IIRucaparib + NivolumabActive, not recruitingEpithelia ovarian cancer, fallopian tube cancer, primary peritoneal cancer, HGSCd and endometrioid adenocarcinoma
PARPi-immunotherapyYesNCT02849496IIOlaparib + AtezolizumabRecruitingLocally advanced unresectable; metastatic non-HER2-positive breast cancer
PARPi- epigenetic drugsNo     
PARPi- HSP90 inhibitorsNo     
PARPi-WEE1 inhibitorsYesNCT03579316IIOlaparib + AZD1775RecruitingRecurrent fallopian tube, ovarian and primary peritoneal cancers
PARPi-WEE1 inhibitorsYesNCT04197713IOlaparib + AZD1775Not yet recruitingAdvanced solid tumors with selected mutations and PARP Resistance
PARPi-WEE1 inhibitorsYesNCT02576444IIOlaparib + AZD1775Active, not recruitingTumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53
PARPi-WEE1 inhibitorsYesNCT02511795IOlaparib + AZD1775CompletedRefractory solid tumors; Relapsed SCLC
PARPi-ATR inhibitorsYesNCT02576444IIOlaparib + AZD6738Active, not recruitingTumors harboring mutations leading to dysregulation of the PI3K/AKT pathway
PARPi-ATR inhibitorsYesNCT04065269IIOlaparib + AZD6738RecruitingGynaecological cancers
PARPi-ATR inhibitorsYesNCT03787680IIOlaparib + AZD6738RecruitingProstate cancer
PARPi-WEE1/ATR inhibitorsYesNCT03330847IIOlaparib + AZD6738/ AZD1775RecruitingMetastatic triple negative breast cancer
PARPi-ATR inhibitorsYesNCT03878095IIOlaparib + AZD6738RecruitingIDH1 and IDH2 mutant tumors
PARPi-ATR inhibitorsYesNCT03462342IIOlaparib + AZD6738RecruitingHGSC
PARPi-ATR inhibitorsYesNCT03428607IIOlaparib + AZD6738Active, not recruitingSCLC
PARPi-ATR inhibitorsYesNCT03682289IIOlaparib + AZD6738RecruitingClear cell renal cell cancer; Metastatic renal cell cancer; Metastatic urothelial cancer; Metastatic pancreatic cancer; Locally advanced pancreatic cancer
  1. aWBRT: Whole Brain Radiation Therapy; bNSCLC: Non-Small Cell Lung Cancer; cSCLC: Small Cell Lung Cancer; dHGSC: High Grade Serous Carcinoma